Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guerin (BCG)

Trial Profile

Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guerin (BCG)

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Oportuzumab monatox (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Viventia Biotechnologies
  • Most Recent Events

    • 02 Jul 2015 According to Viventia Biotechnologies media release, clinical results were published in the Journal of Urology.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top